TABLE 2.

Antifungal activity of micafungin and anidulafungin against the five isolates before and after progressive micafungin exposure^a

Exposure	Result(s) for indicated isolate
	CG1		CG2		CG3		CG4		CG5
	EUCAST MIC (μg/ml) (MYC/AND)	fks2 mutation	EUCAST MIC (μg/ml) (MYC/AND)	fks2 mutation	EUCAST MIC (μg/ml) (MYC/AND)	fks2 mutation	EUCAST MIC (μg/ml) (MYC/AND)	fks2 mutation	EUCAST MIC (μg/ml) (MYC/AND)	fks2 mutation
Initial	0.015/0.062	WT	0.015/0.062	WT	0.015/0.062	WT	0.015/0.062	WT	0.015/0.062	WT
Subsequent (MYC concn in plates, μg/ml)
0.031	0.015/0.031	WT	0.015/0.062	WT	0.015/0.062	WT	0.015/0.031	WT	0.015/0.031	WT
0.062	0.5/2	S663P D666Y	0.015/0.062	WT	0.015/0.125	WT	0.015/0.062	WT	0.015/0.062	WT
0.125	1/2	S663P	0.125/0.5	S663Y	0.031/0.25	WT	2/2	Del F658	2/2	Del F658
0.25	1/2	S663P	0.125/1	S663Y	0.031/0.5	Del F658	2/2	Del F658	2/2	Del F658
0.5	2/2	S663P	0.25/2	S663Y	0.031/1	Del F658	2/2	Del F658	2/2	Del F658
1	2/4	S663P	0.5/2	S663Y	0.031/1	Del F658	2/2	Del F658	2/4	Del F658
2	4/4	S663P	1/2	S663Y	0.062/1	Del F658	2/2	Del F658	4/4	Del F658
Subsequent geometric mean of MICs	0.74/1.34		0.12/0.55		0.03/0.37		0.49/0.67		0.55/0.82

^aMYC, micafungin; AND, anidulafungin; Del, deletion. Boldface characters represent MICs above the clinical breakpoints and FKS point mutations.